• Neurogene mapped out a longer operating runway into the first quarter of 2029 following a public equity offering expected to generate about $134.8 million in net proceeds.
• The financing centers on 3,500,000 common shares priced at USD 30 per share.
• It also includes pre-funded warrants covering up to 666,666 shares priced at USD 30 per share, net of a USD 0.000001 exercise price.
• Underwriters exercised in full a 30-day option for an additional 624,999 shares, with the deal set to close July 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001404644-26-000050), on July 02, 2026, and is solely responsible for the information contained therein.